Search research articles
Contact Us
Filters
Showing results (1-10 of 130) with videos related to
Page
of 13
Sort By:
Pharmacological Research
|
May 25, 2005
Clinical perspectives of PARP inhibitors
Grazia Graziani, Csaba Szabó
Cancers
|
November 26, 2022
Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints
Ornella Franzese, Grazia Graziani
Cancers
|
December 7, 2018
Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
Isabella Faraoni, Grazia Graziani
Pharmacological Research
|
March 14, 2007
Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk?
Lucio Tentori, Grazia Graziani
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
|
August 11, 2001
Telomerase as a potential anticancer target: growth inhibition and genomic instability
Isabella Faraoni, Grazia Graziani
Pharmacological Research
|
May 25, 2005
Chemopotentiation by PARP inhibitors in cancer therapy
Lucio Tentori, Grazia Graziani
Current Medicinal Chemistry
|
June 8, 2002
Pharmacological strategies to increase the antitumor activity of methylating agents
Lucio Tentori, Grazia Graziani
Current Medicinal Chemistry
|
January 20, 2009
Recent approaches to improve the antitumor efficacy of temozolomide
Lucio Tentori, Grazia Graziani
Molecular Cancer Therapeutics
|
March 18, 2004
Correspondence re: DC Lev et al., Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther, 2003;2(8):753-63
Lucio Tentori, Grazia Graziani
Frontiers in Oncology
|
June 20, 2015
Neuropilin-1 as Therapeutic Target for Malignant Melanoma
Grazia Graziani, Pedro M Lacal
Page
of 13
Search research articles
Search
Showing results (1-10 of 130) with videos related to
Sort By:
Page
of 13
Pharmacological Research
|
May 25, 2005
Clinical perspectives of PARP inhibitors
Grazia Graziani, Csaba Szabó
Cancers
|
November 26, 2022
Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints
Ornella Franzese, Grazia Graziani
Cancers
|
December 7, 2018
Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
Isabella Faraoni, Grazia Graziani
Pharmacological Research
|
March 14, 2007
Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk?
Lucio Tentori, Grazia Graziani
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
|
August 11, 2001
Telomerase as a potential anticancer target: growth inhibition and genomic instability
Isabella Faraoni, Grazia Graziani
Pharmacological Research
|
May 25, 2005
Chemopotentiation by PARP inhibitors in cancer therapy
Lucio Tentori, Grazia Graziani
Current Medicinal Chemistry
|
June 8, 2002
Pharmacological strategies to increase the antitumor activity of methylating agents
Lucio Tentori, Grazia Graziani
Current Medicinal Chemistry
|
January 20, 2009
Recent approaches to improve the antitumor efficacy of temozolomide
Lucio Tentori, Grazia Graziani
Molecular Cancer Therapeutics
|
March 18, 2004
Correspondence re: DC Lev et al., Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther, 2003;2(8):753-63
Lucio Tentori, Grazia Graziani
Frontiers in Oncology
|
June 20, 2015
Neuropilin-1 as Therapeutic Target for Malignant Melanoma
Grazia Graziani, Pedro M Lacal
Page
of 13